60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
暂无分享，去创建一个
F. Carrat | J. Pawlotsky | F. Zoulim | D. Samuel | S. Pol | D. Larrey | H. Fontaine | M. Bourlière | C. Hézode | T. Poynard | L. Alric | V. Canva | G. Riachi | J. Bronowicki | V. Ledinghen | P. Bernard | S. Métivier | J. Raabe | C. Dorival | Y. Barthe | J. Gournay | M. Bourliere